Help your eligible patients save on VYZULTA*

Bausch + Lomb has aligned with Walgreens to help eligible patients save.
30-DAY SUPPLY
2.5 mL bottle
$35 CO-PAY*
IF COVERED BY AN
INSURANCE PLAN
$45 CO-PAY*
IF NOT COVERED BY AN
INSURANCE PLAN
For a 60-day supply (5 mL bottle):
Most eligible commercially insured patients pay no more than a $70 co-pay if covered by an insurance plan and no more than a $90 co-pay if not covered by an insurance plan.*
Discounted pricing is available for eligible uninsured patients.*
*Terms and conditions apply.
Please see eligibility criteria and terms and conditions.

A simple process

STEP 1

SEND scripts to local Walgreens or participating independent pharmacy.

STEP 2

OFFER eligible patients a co-pay card, or they can download a coupon at vyzultacoupon.com

STEP 3

ACTIVATE the Bausch + Lomb Access coupon by having your eligible patients call 1-844-864-3015 or visit vyzultacoupon.com

STEP 4

TELL your eligible patients to take it to Walgreens or participating independent pharmacy and pick up the prescription.

Help patients locate a participating pharmacy

  • Web-based Pharmacy Locator
  • Quickly search and locate the nearest Walgreens or independent pharmacy participating in the Bausch + Lomb Access Program
  • Utilize the Pharmacy Locator by clicking here

Download the Patient Guide for getting started with VYZULTA

Patient Guide
INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

SEE MORE

INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation